4. start of new thread. 4, page-107

re: 4. bio chem paper validates prana science. 4 JOURNAL OF BIOLOGICAL CHEMISTRY PAPER
FURTHER VALIDATES PRANA SCIENCE

Melbourne, Australia – October 15, 2004: Prana Biotechnology Limited (NASDAQ:
PRAN, ASX: PBT), today announced that the Journal of Biological Chemistry has published a new paper in its September 30 edition called ‘Clioquinol Mediates Copper Uptake and Counteracts Cu Efflux Activities of the Amyloid Precursor Protein of Alzheimer’s Disease.’

The paper further supports Prana’s theory that PBT-1 (clioquinol) slows down the progression
of Alzheimer’s disease.
Based on the hypothesis that beta amyloid is a key player in the onset and progression of Alzheimer’s disease, Prana maintains that it is the inappropriate interaction of beta amyloid with brain metals, copper and zinc, that leads to the progression associated with the disease.

Unlike current approved Alzheimer’s therapies that largely treat the symptoms of the disease, PBT-1, PBT-2 and Prana’s additional MPACs (Metal Protein Attenuating Compounds) hold promise to help prevent the progression of the disease.

The newly published paper helps clarify the normal role of Amyloid Precursor Protein (APP), the precursor of amyloid beta protein that is the primary constituent of the senile plaques that are characteristically found in Alzheimer’s disease brains.

APP appears to be a critical regulator of intracellular Cu homeostasis. The authors also show that oral treatment of transgenic mice with clioquinol (also known as PBT-1) does not result in a depletion of Cu
and Zn systemically suggesting that PBT-1 does not act as a metal chelator, but instead may be redistributing these metals from the amyloid plaques back to cells.

Rudolph E. Tanzi, Ph.D., Director, Genetics and Aging Research Unit, Massachusetts General Hospital, Professor of Neurology, Harvard Medical School and co-founding scientist of Prana Biotechnology, commented, "The new findings showing that PBT-1 can act therapeutically by facilitating copper uptake into cells could be clinically very beneficial for treating Alzheimer’s disease when taken together with it's ability to clear senile plaques."

About Prana Biotechnology Limited.
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in
September 2002.

Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.
For further information, please visit our web site at www.pranabio.com.
###